FINTEPLA is a prescription medicine used to treat the seizures associated with Dravet syndrome in patients 2 years of age and older. FINTEPLA is a federally controlled substance (C-IV) because it contains fenfluramine. Keep FINTEPLA in a safe place to prevent misuse, abuse, and protect it from theft.
INDICATIONS AND USAGE. ACTIQ® oral transmucosal lozenge, CII is indicated for the management of breakthrough pain in cancer patients 16 years of age
Find information on Adzenys XR-ODT delivery system, dosing, adverse reactions, and safety data. Learn about savings and support available to your patients. View Important Safety Information including Boxed WARNING for abuse and dependence.
BELBUCA® (Buprenorphine) is the first oral formulation of buprenorphine proven to deliver consistent analgesia and tolerability. Rethink Relief.
BUNAVAIL (buprenorphine and naloxone) buccal film is a citrus flavored oral transmucosal form of buprenorphine, an opioid partial agonist, and naloxone, an opioid antagonist, intended for application to the buccal mucosa.
CASSIPA film contains buprenorphine, a partial‐opioid agonist, and naloxone, an opioid antagonist, and is indicated for the maintenance treatment of opioid dependence.
The DrugRelief® percutaneous electrical nerve field stimulator (PNFS) is designed to administer auricular neurostimulation treatment ... Products & Applications.
Information for prescribers about the organizations and Surgeon General advice to co-prescribe naloxone to patients who will have opioids. Also includes the Surgeon General’s speech on opioids and co-prescribing naloxone.
Discover Butrans, a Schedule III, extended-release opioid. See Full Prescribing Info, Safety Info & Boxed Warning.
Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products that contain alcohol while taking EMBEDA.
Physicians seeking information about EVEKEO CII (amphetamine sulfate), visit the official HCP website here. See full safety and abuse information.
Information for physicians about an analgesic therapy that treats multiple sources of pain. Please see Full Prescribing Information and Important Safety Information.
Learn about Mydayis, an extended-release MAS formulation. Not for use in ages ?12. See Safety Info & Abuse Warning.
Discover Hysingla ER Extended-Release Tablets CII, a non-APAP hydrocodone. See Full PI, Medication Guide & Boxed Warning.
LUCEMYRA (lofexidine), an oral tablet, is a central alpha 2-adrenergic agonist that reduces the release of norepinephrine to suppress the neurochemical surge that produces opioid withdrawal.
Kadian. The U.S. Prescribing Information in this product database represents the current product labeling information as of the date of the document. While every ...
AVINZA is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which ...
CHANTIX is contraindicated in patients with a history of serious hypersensitivity or skin reactions to CHANTIX. Postmarketing reports of serious or clinically significant neuropsychiatric adverse events have been reported in patients treated with CHANTIX. These included changes in mood (including depression and mania)
Prolonged use of PERCOCET during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise ...
OXAYDO® (oxycodone HCl) tablets CII — a formulation of immediate-release oxycodone that DISCOURAGES INTRANASAL ABUSE VIA SNORTING. OXAYDO is indicated for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.